RMIT scientists in Melbourne have led an international collaboration that potentially unlocks better treatment of viral diseases, including the flu and common cold.
The results were published in the prestigious scientific and medical journal Nature Communications.
Each year the flu virus sends 13,500 Australians to hospital and causes more than 3000 deaths among those aged over 50. The global burden is also staggering, with more than 5 million cases of infection annually with up to 10 per cent resulting in death.
The RMIT senior authors, Dr Stavros Selemidis (ARC Future Fellow) and Dr Eunice To (first author), collaborated with Professor Doug Brooks from University South Australia, Professor John O’Leary from Trinity College Dublin, Monash University’s Professor Christopher Porter, and other scientists and clinicians to investigate how viruses cause disease in humans.
The researchers discovered that a 1.5 billion-year-old cell biological process found in plants, fungi and mammals enhances viral disease in mice and highly likely also in humans. They identified a protein, Nox2 oxidase, that is activated by viruses, including influenza, rhinovirus (the common cold), dengue and HIV.
Once activated, Nox2 oxidase suppresses the body’s key antiviral reaction and its ability to fight and clear the viral infection, which in turn results in a stronger or more virulent disease in mice.
The study also investigated a new prototype drug to treat these debilitating viral diseases.
The researchers found that the Nox2 oxidase protein activated by the viruses is located in a cell compartment called endosomes. They carefully modified a chemical that inhibits or restrains the activity of Nox2 oxidase.
Their customised drug was found to be very effective at suppressing disease caused by influenza infection.
Selemidis, head of the Oxidant and Inflammation Biology Group within the Chronic Infectious and Inflammatory Diseases program at RMIT, said: “Current treatment strategies are limited as they specifically target circulating viruses and have either unknown or very little effect against new viruses that enter the human population.
“We have identified a protein of the immune system that contributes to the disease caused by flu viruses irrespective of their strain.
“We also developed a novel drug delivery system to target this protein, which drastically alleviated the burden of viral disease.
“The strength of this work is the multidisciplinary approach taken and the degree of collaboration. It includes researchers and clinicians from eight universities across Australia, the United States and Ireland.
“This work attracted considerable interest at the NADPH Oxidase GORDON conference in the USA last year.”
To said: “This work identifies a treatment strategy that has the potential to alleviate the symptoms caused by some of the most devastating viruses worldwide, including the flu.”
The Latest on: Viral diseases
- Moderna Ships a New COVID-19 Vaccine for Testing Against More Infectious Varianton February 24, 2021 at 6:00 pm
Massachusetts-based biotech Moderna announced that has shipped a new version of its already-authorized COVID-19 vaccine to testing sites. The new vaccine is one aspect of a three-part strategy the ...
- A baby with COVID-19 had 51,000 times more viral particles than other young patients, and experts aren't sure whyon February 24, 2021 at 6:00 pm
A newborn in Washington, DC with severe COVID-19 was found to have a new variant of the virus and massive viral load. Researchers are puzzled.
- Rare disease research making advancements despite lack of fundingon February 24, 2021 at 4:11 pm
Despite little attention or investment from pharmaceutical companies, The Jackson Laboratory's Rare and Orphan Disease Center is making progress ...
- Baystate infectious disease head: ‘The future is bright’on February 24, 2021 at 2:01 pm
On March 5, 2020, the head of the Infectious Disease Division at Baystate Medical Center in Springfield said people needed to “prepare not panic” for the pandemic. Almost a year later, Dr. Armando ...
- Moderna to begin trial of new COVID vaccine to address virus variant first found in South Africaon February 24, 2021 at 1:22 pm
Moderna's trial of a new COVID-19 vaccine will target the virus variant that first emerged in South Africa. Other vaccine makers plan similar studies.
- Global Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period - by PMIon February 24, 2021 at 7:39 am
Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR of 13.1%. Rare disease is any disease that ...
- Infectious disease outbreak prediction using media articles with machine learning modelson February 24, 2021 at 3:20 am
When a newly emerging infectious disease breaks out in a country, it brings critical damage to both human health conditions and the national economy. For this reason, apprehending which disease will ...
- Report highlights tremendous burden from infectious diseases in SEAR countrieson February 23, 2021 at 7:26 am
Researchers at CDDEP, in collaboration with leading experts in the field, have produced the "Infectious Diseases in the South-East Asia Region" report, which examines cross-boundary challenges in ...
- Infectious disease expert explains benefits of Johnson & Johnson vaccineon February 22, 2021 at 1:06 pm
Pfizer and Moderna COVID-19 vaccines have already rolled out in the U.S. But, the country is still waiting on Johnson & Johnson to begin its roll out.
- Infectious disease standard for health care industry a priority, OSHA tells courton February 22, 2021 at 11:58 am
OSHA is prioritizing an infectious diseases standard for the health care industry, according to a motion filed Feb. 16 in the 9th U.S. Circuit Court of Appeals.
via Google News and Bing News